Search Patents
  • Canine respiratory coronavirus (CRCV) spike protein
    Patent number: 7981427
    Abstract: A canine respiratory coronavirus (CRCV) that is present in the respiratory tract of dogs with canine infectious respiratory disease and which has a low level of homology to the enteric canine coronavirus, but which has a high level of homology to all bovine coronavirus strains (e.g., Quebec and LY138) and human coronavirus strain OC43.
    Type: Grant
    Filed: September 26, 2008
    Date of Patent: July 19, 2011
    Assignee: The Royal Veterinary College
    Inventors: John Brownlie, Victoria Jane Chalker, Kerstin Erles
  • Neutralizing Antibodies that Bind the SARS-COV-2 S Protein
    Publication number: 20230416343
    Abstract: The present disclosure provides fully human antibodies that specifically bind the spike (S) protein of the SARS-CoV-2 coronavirus with high affinity, or antigen-binding proteins derived from such antibodies, and uses thereof. Included are anti-spike protein antibodies, antibody fragments, and single-chain antibodies, that are coronavirus neutralizing antibodies, as well as pharmaceutical compositions that include such antibodies and antibody fragments. Methods for using the anti-spike protein antibodies include methods of treating or preventing infection with a coronavirus, such as the SARS-CoV-2 coronavirus, by administering an antibody or antibody fragment as disclosed herein, including by intranasal delivery. Methods and compositions for treating or preventing coronavirus infection by administering a composition that includes a nucleic acid construct that encodes a neutralizing antibody are also provided.
    Type: Application
    Filed: August 6, 2021
    Publication date: December 28, 2023
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Henry Hongjun Ji, Robert Allen, Heyue Zhou, Yanliang Zhang, Yanwen Fu, Wenzhong Guo, Hui Xie, Xia Cao, Lucy Lu, Donghui Li, Reyna Lim, Arthur Ledesma, Daniel Lee
  • ENGINEERING CORONAVIRUS SPIKE PROTEINS AS VACCINE ANTIGENS, THEIR DESIGN AND USES
    Publication number: 20230226170
    Abstract: A vaccine for preventing CoV infection includes at least one DNA, RNA or protein sequence for S protein with at least one modification which is a full deletion or partial deletion of the SI region or a partial or full replacement of the SI region. A method of vaccinating a mammal subject against infection from at least one group of CoV includes separating a broad group of CoV into homology groups, creating a modified S protein containing at least one modification at its S1 region, and identifying at least one consensus sequence for each homology group which has a sequence identity of greater than 60% to all other members of the homology group. The consensus sequence is a protein sequence for the modified S protein, a DNA sequence encoding the modified S protein, and an RNA sequence encoding the modified S protein.
    Type: Application
    Filed: May 12, 2021
    Publication date: July 20, 2023
    Inventors: Uwe D. STAERZ, Daniel F. PRESTON, Yan QI
  • NUCLEIC ACID VACCINE AGAINST THE SARS-CoV-2 CORONAVIRUS
    Publication number: 20220401550
    Abstract: The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-CoV-2), comprising a nucleic acid construct encoding a SARS-CoV-2 coronavirus Spike (S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in human.
    Type: Application
    Filed: August 11, 2022
    Publication date: December 22, 2022
    Inventors: Etienne SIMON-LORIERE, Matthieu PROT, Xavier MONTAGUTELLI
  • NUCLEIC ACID VACCINE AGAINST THE SARS-COV-2 CORONAVIRUS
    Publication number: 20240042014
    Abstract: The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-CoV-2), comprising a nucleic acid construct encoding a SARS-CoV-2 coronavirus Spike (S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in human.
    Type: Application
    Filed: September 12, 2023
    Publication date: February 8, 2024
    Inventors: Etienne SIMON-LORIERE, Matthieu PROT, Xavier MONTAGUTELLI
  • NUCLEIC ACID VACCINE AGAINST THE SARS-COV-2 CORONAVIRUS
    Publication number: 20240024462
    Abstract: The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-CoV-2), comprising a nucleic acid construct encoding a SARS-CoV-2 coronavirus Spike (S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in human.
    Type: Application
    Filed: September 12, 2023
    Publication date: January 25, 2024
    Inventors: Etienne SIMON-LORIERE, Matthieu PROT, Xavier MONTAGUTELLI
  • NUCLEIC ACID VACCINE AGAINST THE SARS-COV-2 CORONAVIRUS
    Publication number: 20240000922
    Abstract: The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-CoV-2), comprising a nucleic acid construct encoding a SARS-CoV-2 coronavirus Spike (S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in human.
    Type: Application
    Filed: July 12, 2023
    Publication date: January 4, 2024
    Inventors: Etienne SIMON-LORIERE, Matthieu PROT, Xavier MONTAGUTELLI
  • Nucleic acid vaccine against the SARS-CoV-2 coronavirus
    Patent number: 11911462
    Abstract: The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-CoV-2), comprising a nucleic acid construct encoding a SARS-CoV-2 coronavirus Spike (S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in human.
    Type: Grant
    Filed: July 12, 2023
    Date of Patent: February 27, 2024
    Assignee: INSTITUT PASTEUR
    Inventors: Etienne Simon-Loriere, Matthieu Prot, Xavier Montagutelli
  • Nucleic acid vaccine against the SARS-CoV-2 coronavirus
    Patent number: 11969467
    Abstract: The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-CoV-2), comprising a nucleic acid construct encoding a SARS-CoV-2 coronavirus Spike (S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in human.
    Type: Grant
    Filed: September 12, 2023
    Date of Patent: April 30, 2024
    Assignee: INSTITUT PASTEUR
    Inventors: Etienne Simon-Loriere, Matthieu Prot, Xavier Montagutelli
  • Nucleic acid vaccine against the SARS-CoV-2 coronavirus
    Patent number: 11759516
    Abstract: The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-CoV-2), comprising a nucleic acid construct encoding a SARS-CoV-2 coronavirus Spike (S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in human.
    Type: Grant
    Filed: August 11, 2022
    Date of Patent: September 19, 2023
    Assignee: INSTITUT PASTEUR
    Inventors: Etienne Simon-Loriere, Matthieu Prot, Xavier Montagutelli
  • Nucleic acid vaccine against the SARS-CoV-2 coronavirus
    Patent number: 11964013
    Abstract: The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-CoV-2), comprising a nucleic acid construct encoding a SARS-CoV-2 coronavirus Spike (S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in human.
    Type: Grant
    Filed: September 12, 2023
    Date of Patent: April 23, 2024
    Assignee: INSTITUT PASTEUR
    Inventors: Etienne Simon-Loriere, Matthieu Prot, Xavier Montagutelli
  • BLOCKADE OF SARS-COV-2 INFECTION USING HYDROCARBON STAPLED PEPTIDES
    Publication number: 20240052330
    Abstract: The disclosure is directed to methods of inhibiting coronavirus infection using a hydrocarbon stapled peptide which is a peptidomimetic of the human angiotensin-converting enzyme 2 (hACE2). The hydrocarbon stapled peptide binds to the receptor binding domain (RBD) of a coronavirus spike protein (S) and inhibits binding of the coronavirus to hACE2 expressed on the surface of host cells.
    Type: Application
    Filed: December 22, 2021
    Publication date: February 15, 2024
    Inventors: Yu TIAN, Sicheng JIANG, Jeffrey A. HUBBELL, Matthew A. TIRRELL, James L. LABELLE
  • CORONAVIRUS VACCINE FORMULATIONS
    Publication number: 20210228708
    Abstract: Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
    Type: Application
    Filed: February 8, 2021
    Publication date: July 29, 2021
    Inventors: Gale SMITH, Michael J. MASSARE, Jing-Hui TIAN
  • HUMANIZED ACE2-FC FUSION PROTEIN FOR TREATMENT AND PREVENTION OF SARS-COV-2 INFECTION
    Publication number: 20230235007
    Abstract: Disclosed herein are ACE2-Fc fusion polypeptides that contain at least one binding site for a spike protein of a coronavirus and methods of using such for therapeutic and/or diagnostic purposes. Also provided herein are methods for producing such fusion polypeptides.
    Type: Application
    Filed: June 15, 2021
    Publication date: July 27, 2023
    Inventors: Pan-Chyr YANG, Sui-Yuan CHANG, Kuo-Yen HUANG
  • CORONAVIRUS VACCINE FORMULATIONS
    Publication number: 20230330216
    Abstract: Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
    Type: Application
    Filed: December 5, 2022
    Publication date: October 19, 2023
    Inventors: Gale SMITH, Michael J. MASSARE, Jing-Hui TIAN
  • CORONAVIRUS VACCINE FORMULATIONS
    Publication number: 20210228709
    Abstract: Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
    Type: Application
    Filed: March 18, 2021
    Publication date: July 29, 2021
    Inventors: Gale SMITH, Michael J. MASSARE, Jing-Hui TIAN
  • ANTIBODIES
    Publication number: 20240043507
    Abstract: The present invention relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2, and methods and uses thereof in the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19.
    Type: Application
    Filed: February 4, 2022
    Publication date: February 8, 2024
    Inventors: Gavin SCREATON, Juthathip MONGKOLSAPAYA
  • CORONAVIRUS VACCINE FORMULATIONS
    Publication number: 20230070886
    Abstract: Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
    Type: Application
    Filed: January 27, 2021
    Publication date: March 9, 2023
    Inventors: Gale SMITH, Michael J. MASSARE, Jing-Hui TIAN
  • CORONAVIRUS VACCINE FORMULATIONS
    Publication number: 20220332765
    Abstract: Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
    Type: Application
    Filed: March 22, 2022
    Publication date: October 20, 2022
    Inventors: Gale SMITH, Michael J. MASSARE, Jing-Hui TIAN
  • CORONAVIRUS VACCINE FORMULATIONS
    Publication number: 20220125914
    Abstract: Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
    Type: Application
    Filed: January 10, 2022
    Publication date: April 28, 2022
    Inventors: Gale SMITH, Michael J. MASSARE, Jing-Hui TIAN
Narrow Results

Filter by US Classification